Contribute Try STAT+ Today

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far. This is cause for a toast, since the end of the week is no longer so far away. So please join us as we reach for a cup of stimulation — the oh-so seasonal pumpkin spice is our choice du jour — and drink to what will hopefully be a productive day. On that note, we have assembled a few items of interest to help you get started. We hope your day goes well and you conquer the world. Meanwhile, stay safe — and wear a mask. …

Sanofi (SNY) and GlaxoSmithKline (GSK) plan to make 200 million doses of their Covid-19 vaccine candidate available to the COVAX vaccine allocation plan co-led by GAVI and the World Health Organization, Reuters notes. COVAX aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan. Glaxo and Sanofi signed a $2.1 billion deal with the U.S. to supply it with more than 100 million doses of its vaccine candidate, and also have deals with the European Union and the U.K.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy